Clinical Monitoring During Treatment Sessions

What monitoring is for

During treatment sessions with psychedelic drugs, people can be in a vulnerable state for several hours or longer, according to the FDA. [1] Monitoring means trained staff stay with the person, observe effects and body signs, and can respond to distress or a medical problem. This page describes research and regulated settings. It is not a guide for anyone to supervise, or take part in, use outside those settings.

Urgent note

If someone has chest pain, trouble breathing, a seizure, confusion that does not clear, or thoughts of self-harm after taking any substance, call 911 (US) or local emergency services. In the US, call or text 988 for a crisis, or Poison Help at 1-800-222-1222. See when to seek urgent help.

What the FDA expects in trials

For trials under an FDA research application, the guidance expects safety monitoring that includes: [1]

• Observation by two monitors for the whole treatment session.
• A lead monitor who is a health care provider with graduate-level training and clinical experience in psychotherapy, licensed to practice independently, and an assistant monitor with a nursing or bachelor's degree and at least 1 year of clinical experience in a licensed mental health setting.
• If the lead monitor is not a physician, a licensed on-call physician able to reach the site within 15 minutes.
• Documentation of the incidence, duration and severity of all central nervous system effects, including expected psychedelic effects, whether the experience is called positive, favorable or neutral.
• Assessment of effects on orientation, thought and perception over time, to inform monitoring, safety of discharge and impact on driving.
• For drugs that act on the 5-HT2B receptor and are given chronically, heart-valve and pulmonary-pressure checks, though the guidance says it is not clear this applies to psychedelics. [1]

The FDA calls these expectations for sponsors, not rules for the public. The guidance is nonbinding. [1]

What researchers recommend

Published safety guidelines list interpersonal support from at least two study monitors during the session, a safe physical environment, and follow-up that asks about hallucinogen persisting perception disorder, a rare condition. [2] The most likely risk named is overwhelming distress, which could lead to dangerous behavior such as leaving the study site. [2]

What trials observed

• In the MDMA phase 3 trial, blood pressure and pulse rose temporarily and in a dose-dependent way during sessions compared with placebo. [3] Seven of 104 participants had a severe adverse event. [4]
• In the psilocybin treatment-resistant depression trial, 77% of participants had an adverse event, and suicidal ideation or behavior or self-injury occurred in all dose groups. [5]

These numbers show why monitoring continues after the session as well as during it.

Oregon's licensed program

Oregon Health Authority (read 2026-10-22) says clients must stay at the service center for a minimal time based on the dose they consume, and must complete a transportation plan before the session. [6] Facilitators follow up within 72 hours. [6] Monitoring rules in other places may differ; this is not legal advice.

An approved medicine for comparison

Esketamine nasal spray (Spravato) is an FDA-approved medicine, not a psychedelic. Its Medication Guide says the provider must monitor the patient for at least 2 hours after a dose and will decide when the patient may leave. It also says blood pressure is checked before and for at least 2 hours after a dose. [7] See esketamine and ketamine.

What monitoring cannot do

It does not remove risk, and it does not make a substance safe outside a monitored setting. The guidance asks sponsors to think about risks of nonmedical use and accidental exposure. [1] Monitoring also does not settle who is qualified; see therapist and practitioner qualifications.

Related guides

• Screening and eligibility
• What is psychedelic-assisted therapy?
• Acute psychological distress